LCS
URGN icon

Levin Capital Strategies’s UroGen Pharma URGN Stock Holding History

Levin Capital Strategies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$13.7K – 250
2025
Q2 		$13.7K Buy
+1,000
New +$9.6K ﹤0.01% 201

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Levin Capital Strategies's URGN Position: Q3 2025 in Review

Levin Capital Strategies sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 1,000 shares — an estimated $13.7K sold.

Levin Capital Strategies first reported a position in URGN in Q2 2025 and held it in 1 quarter. The position peaked at $13.7K in Q2 2025. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Levin Capital Strategies reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Levin Capital Strategies sold 1,000 UroGen Pharma shares in Q3 2025, an estimated $13.7K.
  • Levin Capital Strategies first reported a position in UroGen Pharma in Q2 2025 and held it in 1 quarter.
  • Levin Capital Strategies's UroGen Pharma position peaked at $13.7K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Levin Capital Strategies's 13F filing for Q3 2025, filed 7 Nov 2025.